Leaving the Wheelchair Without Crutches: Eve and the Self-Balancing Exoskeleton

Standing up from a wheelchair, crossing a room and looking a friend in the eye: for hundreds of thousands of people paralysed from the legs down, that ordinary act remains out of reach. The French company Wandercraft says it has made it possible without a single crutch. Its device, called Eve, is a personal exoskeleton that balances itself: motors at the hips, knees and ankles correct posture continuously, so the user keeps both hands free instead of clutching canes.

On 25 June 2026, the company announced a distribution deal with National Seating & Mobility, a US network of more than one hundred and eighty branches specialised in complex mobility equipment. The aim is to deliver Eve to patients' homes as soon as the Food and Drug Administration gives its clearance, expected over the summer. What remains to be seen is what this promise of walking again is really worth, and what it costs.

A robot that stands up for you

The idea of an exoskeleton for paralysed people is not new, but earlier models almost all demanded crutches: without them, the wearer toppled over. The system offloaded part of the balancing onto the user's arms, which excluded anyone lacking upper-body strength and ruled out having one's hands busy with anything else.

Eve overturns that trade-off. An onboard control unit recomputes the whole posture several times a second and drives the motors so that the machine, and the person it carries, does not fall. The device adapts its gait to the surface, concrete, carpet or tile, and absorbs small imbalances before they become a fall. It is this active stability, borrowed from humanoid robotics, that lets the canes go.

Wandercraft knows the ground. For years its first exoskeleton, Atalante, has been used in rehabilitation centres, walking patients again under a physiotherapist's eye in a hospital setting. Eve is the attempt to move that technology out of the treatment room and into an apartment hallway.

Standing tall, and what it mends

The most immediate benefit fits a phrase from the company itself: being able to talk to loved ones at eye level, do the shopping, walk alongside the people you love. After years spent seated, looking at others from below is not a detail, it is an imposed social position. Returning to the vertical changes one's relationship to space and to people as much as the bare ability to move.

There is also a medical stake that rarely gets airtime. Sitting permanently damages the body: pressure sores, circulatory trouble, bone loss, pain. Standing and walking, even for a limited time each day, eases some of those harms. The exoskeleton does not merely carry a body around, it sets back in motion an organism that the wheelchair freezes.

For those who benefit, the gain in autonomy is concrete: crossing a threshold, reaching a high shelf, moving around at home without depending at every instant on a ramp or an outstretched arm. This is the part of the promise that looks the most solid, because it rests on a simple fact: the device stands up without the arms.

The independence that needs a watcher

The caveat is large, and the company does not hide it: Eve works with the help of a trained companion. The machine balances itself, but it is not used alone. A third person must be present and trained to supervise the walking, handle the unexpected, step in when needed. The promised independence thus comes with a mandatory presence at one's side.

Then comes the question of price. Wandercraft has not published Eve's cost, but its clinical exoskeleton trades above one hundred and fifty thousand dollars. Even if the home version targets a more modest figure, this is an object out of reach without coverage. The partnership with a specialised distributor exists precisely for that: to organise assessment, check eligibility and, one hopes, open a path to reimbursement.

For Eve is not for everyone. The device targets eligible people, spinal cord injuries or severe motor impairments, selected case by case. And until the FDA has ruled, nothing is on sale: the summer 2026 date remains a regulatory bet, not a certainty.

What kind of autonomy, exactly?

A manual wheelchair never runs out of battery and asks for no software update. An exoskeleton does. Swapping one for the other means trading simple, rugged mechanics for a sophisticated electronic system, more capable but more fragile, hanging on a charge, on after-sales service, on a manufacturer that has to stay alive. The autonomy won back on one's legs comes paired with a new dependence on a company and its technology.

This does not disqualify the device, it pins down its nature. Eve is not a universal substitute for the wheelchair, it is one more tool, valuable for those who can benefit, to be used at certain moments of the day. The verticality it restores does not erase the need for help, it shifts it: fewer hands to push, but a watcher to accompany and a machine to maintain.

The walking Eve gives back says something about the age: our most impressive technologies return gestures we thought were lost, yet almost never without conditions. Standing without crutches, yes, provided a trained relative, a sizeable budget and a reliable maker. If the FDA gives its blessing this summer, the real test will begin, not in a laboratory or a demo, but in the daily life of ordinary apartments, where a fall does not get a second take.